BAY-1797 NEW
| Price | $34 | $77 | $129 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-22 |
Product Details
| Product Name: BAY-1797 | CAS No.: 2055602-83-8 |
| Purity: 98.74% | Supply Ability: 10g |
| Release date: 2025/05/22 |
Product Introduction
Bioactivity
| Name | BAY-1797 |
| Description | BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects. BAY-1797 displays no or very weak activity on the other P2X ion channels. |
| In vitro | BAY-1797 inhibits human, mouse, and rat P2X4 in 1321N1 cells (IC50s: 108 nM, 112 nM, and 233 nM). BAY-1797 exerts no measurable activity on hERG and carbonic anhydrase II (both IC50>10 μM). BAY-1797 (10 μM) is also tested against a panel of off-targets, including GPCRs, ion channels, kinases, and transporters. Inhibitory activity against the dopamine transporter (IC50: 2.17 μM) was revealed as the only hit. |
| In vivo | BAY-1797 (12.5-50 mg/kg; p.o.) significantly induces PGE2 levels in the inflamed paw in the mouse Complete Freund’s Adjuvant (CFA) inflammatory pain model. At 50 mg/kg daily, BAY-1797 significantly reduces ipsilateral paw load 24 and 48 hours post-CFA injection. Pharmacokinetic parameters include AUCnorm of 1.06 kg h/L, Vss of 3.67 L/kg, and t1/2 of 2.64 hours. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 250 mg/mL (599.69 mM), Sonication is recommended. |
| Keywords | selective | paw | P2XRs | P2XReceptor | P2X Receptor | P2X | ion | Inhibitor | inhibit | inflamed | human P2X7 | human P2X4 | human P2X3 | human P2X23 | human P2X1 | Freund's | Complete | channel | CFA | BAY-1797 | BAY1797 | BAY 1797 | anti-nociceptive | anti-inflammatory | Adjuvant |
| Inhibitors Related | Gefapixant citrate | Opiranserin hydrochloride | Aurintricarboxylic acid | (E/Z)-Sivopixant | PSB-12062 | ATP disodium salt | Oxatomide | JNJ-42253432 | Ivermectin | Lappaconitine | CTP disodium dihydrate | Brilliant blue G-250 |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $40.00/1KG |
VIP4Y
|
ZhenYiBio Technology Inc
|
2022-01-14 | |
| $0.00/1kg |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-09-26 | |
| $34.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY